INNOVIVE Pharmaceuticals Initiates Pivotal Phase II Clinical Trial with Tamibarotene
11/15/2007 9:07:35 AM
NEW YORK--(BUSINESS WIRE)--INNOVIVE Pharmaceuticals, Inc. (OTCBB:IVPH) today announced that the first patient has been treated in a pivotal Phase II clinical trial evaluating oral Tamibarotene for the treatment of refractory acute promyelocytic leukemia (APL). APL is a type of acute myeloid leukemia. This trial will be conducted under a Special Protocol Assessment (SPA) agreed upon by INNOVIVE and the U.S. Food and Drug Administration (FDA) in August. In conjunction with data from Japanese studies, data from INNOVIVE’s pivotal study of Tamibarotene are expected to form the basis of a New Drug Application (NDA) with the FDA.
comments powered by